How to Relieve Persistent Nasal Congestion in Allergic Rhinitis

Allergic rhinitis—commonly known as hay fever—is a chronic inflammatory condition of the nasal mucosa triggered by exposure to airborne allergens such as pollen, dust mites, mold spores, or animal dander. One of the most persistent and bothersome symptoms is nasal congestion, which results from swelling of the nasal turbinates and increased mucus production due to IgE-mediated immune activation.

Effective management begins with allergen avoidance: using high-efficiency particulate air (HEPA) filters, washing bedding weekly in hot water, minimizing carpeting and soft furnishings, and keeping windows closed during peak pollen seasons. For many patients, however, environmental control alone is insufficient.

First-line pharmacotherapy includes intranasal corticosteroids—such as fluticasone, mometasone, or triamcinolone—which significantly reduce mucosal inflammation and improve airflow when used consistently for at least one to two weeks. Oral or intranasal antihistamines (e.g., loratadine, cetirizine, or azelastine) provide rapid relief of sneezing, itching, and rhinorrhea but offer only modest benefit for congestion. Decongestants like pseudoephedrine or oxymetazoline may be used short-term (≤3 days) to alleviate acute obstruction; prolonged use risks rebound rhinitis and mucosal damage.

For patients with moderate-to-severe, persistent allergic rhinitis uncontrolled by medications, allergen immunotherapy—either subcutaneous (SCIT) or sublingual (SLIT)—represents a disease-modifying intervention. Administered over three to five years, it induces immune tolerance by gradually increasing allergen exposure, thereby reducing symptom burden and medication dependence long term.

When nasal obstruction remains refractory despite optimal medical therapy, structural contributors—such as deviated septum, concha bullosa, or nasal polyps—should be evaluated via anterior rhinoscopy and, if indicated, endoscopic examination. In select cases, surgical interventions like turbinate reduction or septoplasty may be considered adjunctive measures—not primary treatments for allergic inflammation itself.